Ingenol - CAS 30220-46-3
Catalog number:
30220-46-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20H28O5
Molecular Weight:
348.44
COA:
Inquire
Targets:
PKC
Description:
Ingenol, the analogue of Ingenol 3-Angelate found in the seeds of Euphorbia lathyris L, is an extremely weak PKC (protein kinase C) activator ( Ki=30 μM, ED50=27 μM, in vitro). Ingenol has anti-tumor activity when used topically for the treatment of actin
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
White powder
Synonyms:
1A,2,5,5A,6,9,10,10A OCTAHYDRO-5,5A,6-TRIHYDROXY4(HYDROXYMETHYL)1,1,7,9-TETRAMETHYL1H-2,8 AMETHANOCYCLOPENTA[A]CYCLOPROPA[E]CYCLODECEN-11 ONE;1 ALPHA,2,5,5 ALPHA,6,9,10,10 ALPHA-OCTAHYDRO-5,5 ALPHA,6-TRIHYDROXY-4-HYDROXYMETHYL-1,1,7,9-RETRAMETHYL-1H-2,8 A
Solubility:
Soluble in DMSO
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -60℃ for long term (months to years).
MSDS:
Inquire
Application:
Anticancer
Quality Standard:
Enterprise Standard
Shelf Life:
2 years
Boiling Point:
523.8±50.0 °C | Condition: Press: 760 Torr
Melting Point:
299-301°C
Density:
1.33±0.1 g/cm3
InChIKey:
VEBVPUXQAPLADL-POYOOMFHSA-N
InChI:
1S/C20H28O5/c1-9-7-19-10(2)5-13-14(18(13,3)4)12(17(19)24)6-11(8-21)16(23)20(19,25)15(9)22/h6-7,10,12-16,21-23,25H,5,8H2,1-4H3/t10-,12+,13-,14+,15+,16-,19+,20-/m1/s1
Canonical SMILES:
CC1CC2C(C2(C)C)C3C=C(C(C4(C1(C3=O)C=C(C4O)C)O)O)CO
1.United States Food and Drug Administration Product Label Changes.
Kircik L1, Sung JC2, Stein-Gold L3, Goldenberg G2. J Clin Aesthet Dermatol. 2016 Jan;9(1):39-48.
Once a drug has been approved by the United States Food and Drug Administration and is on the market, the Food and Drug Administration communicates new safety information through product label changes. Most of these label changes occur after a spontaneous report to either the drug manufacturing companies or the Food and Drug Administration MedWatch program. As a result, 400 to 500 label changes occur every year. Actinic keratosis treatments exemplify the commonality of label changes throughout the postmarket course of a drug. Diclofenac gel, 5-fluorouracil cream, imiquimod, and ingenol mebutate are examples of actinic keratosis treatments that have all undergone at least one label revision. With the current system of spontaneous reports leading to numerous label changes, each occurrence does not necessarily signify a radical change in the safety of a drug.
2.Italian expert consensus for the management of actinic keratosis in immunocompetent patients.
Peris K1, Calzavara-Pinton PG2, Neri L3, Girolomoni G4, Malara G5, Parodi A6, Piaserico S7, Rossi R8, Pellacani G9. J Eur Acad Dermatol Venereol. 2016 Apr 6. doi: 10.1111/jdv.13648. [Epub ahead of print]
Actinic keratosis (AK) is a common skin disease which can potentially progress to invasive squamous cell carcinoma (iSCC). Given that mortality rates and health-care cost associated with iSCC are substantial, the management of AK represents an important public health issue. Several effective lesion-directed and field-directed treatments are available. Ablative procedures (e.g. cryosurgery, excision, laser ablation, curettage alone or with electrodessication) are considered cost-effective options for solitary lesions. Field-directed therapies (e.g. Ingenol Mebutate, imiquimod, PDT, 5-Fluorouracile, diclofenac 3%, 5-FU + Salicylic acid) can be used over large epidermal surfaces and are directed to treat both individual visible lesions and cancerization fields. In order to provide guidance for management choice in clinical practice, several guidelines concerning the diagnosis and treatment of AK have been published in the past decade. However, the introduction of novel therapeutic options requires continuous updates of recommendations and adaptation to national contexts.
3.Ingenol mebutate gel for the treatment of Bowen's disease: a case report of three patients.
Salleras Redonnet M1, Quintana Codina M1. Dermatol Ther. 2016 Mar 11. doi: 10.1111/dth.12344. [Epub ahead of print]
We report three Bowen's disease (BD) cases treated with ingenol mebutate (IM), a novel topical chemotherapeutic agent approved for the treatment of actinic keratosis (AK) that is available in two doses: 0.015% and 0.05%. Three women diagnosed with BD exhibited a positive response after 2 or 3 day period of IM treatment, depending on lesion location. In the three cases, clinical resolution was observed 4 or 9 weeks posttreatment, and was confirmed with histopathology. Local skin reactions were common the first week after treatment but they resolved spontaneously. In our opinion these cases, along with another case reported in Germany, support the concept of commencing of clinical trials using IM on patients with BD.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PKC Products


CAS 75567-37-2 Ingenol Mebutate

Ingenol Mebutate
(CAS: 75567-37-2)

Ingenol Mebutate is a substance found in the sap of the plant Euphorbia peplus and an inducer of cell death. It is effective for field treatment of actinic kera...

CAS 83314-01-6 Bryostatin 1

Bryostatin 1
(CAS: 83314-01-6)

Bryostatin 1, a structurally unique macrolactone marine natural product, is a protein kinase C (PKC) activator that binds with high affinity (Ki = 1.35 nM). Bry...

CAS 120685-11-2 Midostaurin

Midostaurin
(CAS: 120685-11-2)

Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

CAS 17673-25-5 Phorbol

Phorbol
(CAS: 17673-25-5)

Phorbol, derived from the roots of Euphorbia pekinensis Rupr., as a tumor promoter it is able to activate protein kinase C.

PKC-IN-1
(CAS: 1046787-18-1)

PKC-IN-1 has been found to be a PKCβII inhibitor that probably has biological activity in antineoplastic studies. Ki: 14.9 nM.

CAS 164658-13-3 CGP60474

CGP60474
(CAS: 164658-13-3)

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics rela...

NSC305787
(CAS: 785718-37-8)

NSC305787 is a small molecule inhibitor of PKC. Its IC50 value is 8.3 μM, 9.4 μM, 55 μM for PKCΙ phosphorylation of recombinant ezrin, moesin and radixin. It is...

CAS 60857-08-1 Prostratin

Prostratin
(CAS: 60857-08-1)

Prostratin is an activator of protein kinase C (PKC) and also an activator of nuclear factor KB (NF-KB) mediated through activation of the IKKs (IKB kinases). I...

CAS 125314-64-9 RO31-8220

RO31-8220
(CAS: 125314-64-9)

Ro 31-8220 is a PKC-inhibitor, which inhibits stimulated fluid pinocytosis of human PMNs induced by the PKC-activators phorbol myristate acetate or diacylglycer...

CAS 62996-74-1 Staurosporine

Staurosporine
(CAS: 62996-74-1)

Staurosporine is broad spectrum protein kinase inhibitor. Enzymes inhibited include protein kinase C (IC50 = 3 nM), protein kinase A (IC50 = 7 nM), p60v-src tyr...

NSC305787 hydrochloride
(CAS: 53868-26-1)

NSC305787 hydrochloride is a small molecule inhibitor of PKC (IC50=8.3 μM) that directly inhibits ezrin protein as an approach to prevent tumor metastasis.

CAS 169939-94-0 Ruboxistaurin

Ruboxistaurin
(CAS: 169939-94-0)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

CAS 90365-57-4 (-)-Indolactam V

(-)-Indolactam V
(CAS: 90365-57-4)

(-)-Indolactam V is an indole alkaloid compound which activates protein kinase C (PKC), which strongly directs human ES cell-derived definitive endoderm into pa...

CAS 30220-46-3 Ingenol

Ingenol
(CAS: 30220-46-3)

Ingenol, the analogue of Ingenol 3-Angelate found in the seeds of Euphorbia lathyris L, is an extremely weak PKC (protein kinase C) activator ( Ki=30 μM, ED50=2...

CAS 425637-18-9 Sotrastaurin

Sotrastaurin
(CAS: 425637-18-9)

Sotrastaurin, also known as AEB-701, is an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities....

CAS 163751-35-7 rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate

rac-3-Hexadecanamido-2-methoxypropan-1-o
(CAS: 163751-35-7)

The Pharmacological activity of this molecular is Growth Inhibition of Malignant Cells in vivo and in vitro and cytotoxic properties may result inhibition of pr...

CAS 118072-93-8 Zoledronic Acid

Zoledronic Acid
(CAS: 118072-93-8)

Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins...

CAS 169939-93-9 Ruboxistaurin Hydrochloride

Ruboxistaurin Hydrochloride
(CAS: 169939-93-9)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

CAS 37558-16-0 Phorbol 12,13-dibutyrate

Phorbol 12,13-dibutyrate
(CAS: 37558-16-0)

Phorbol 12,13-dibutyrate, a protein kinase C activator, stimulates the phosphorylation of Na+,K+- ATPase, thereby inhibiting its activity.

CAS 1874276-76-2 LXS196

LXS196
(CAS: 1874276-76-2)

LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under clinical trials for the treatment of uveal melanoma, the most common cancer of the e...

Chemical Structure

CAS 30220-46-3 Ingenol

Quick Inquiry

Verification code

Featured Items